Morten Graugaard Døssing joined Novo Holdings in 2016 and serves as Partner in the company creation team of Novo Seeds where he leads new company formation. He currently serves on the Board of Acesion Pharma, Avilex Pharma, Hoba Therapeutics, NMD Pharma, Stipe Therapeutics, and Syndesi Therapeutics.
Previously, he was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new biotech companies. Earlier in his career, he co-led the life science consulting practice at a Copenhagen-based boutique advisory firm focusing on business development and management consulting. Morten holds an MSc in human biology from the University of Copenhagen.